

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
1	16/NW/0041	197706	SOLAR-1: A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and post-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer which progressed on or after arom	Number Agreed	56	56	Date Agreed	26/02/2020	14	26/02/2020	14	Recruitment Finished	
2	18/EE/0296	250366	A Phase I, Open Label, Randomized, Parallel Group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of =40 and =70 mL/min/1.73m2	Number Agreed	3	3	Date Agreed	16/03/2020	1	16/03/2020	1	Recruitment Finished	
3	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Number Agreed	10	10	Date Agreed	01/05/2020	2	01/05/2020	2	Recruitment Finished	
4	19/EE/0200	265253	A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2)	Number Agreed	72	72	Date Agreed	17/01/2020	9	17/01/2020	9	Recruitment Finished	
5	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (C	Number Agreed	4	4	Date Agreed	09/04/2020	6	09/04/2020	6	Recruitment Finished	
6	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Number Agreed	10	10	Date Agreed	22/07/2020	6	22/07/2020	6	Recruitment Finished	

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
7	17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	Number Agreed	4	4	Date Agreed	05/07/2020	4	05/07/2020	4	Recruitment Finished	
8	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	Number Agreed	12	12	Date Agreed	31/08/2020	0	31/08/2020	0	Recruitment Finished	
9	18/EM/0119	244650	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Number Agreed	12	12	Date Agreed	03/08/2020	4	03/08/2020	4	Recruitment Finished	
10	18/EE/0099	239606	An open-label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not ca	Number Agreed	18	18	Date Agreed	14/09/2020	6	14/09/2020	6	Recruitment Finished	
11	18/WS/0199	253868	A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)	Number Agreed	30	30	Date Agreed	01/10/2020	0	01/10/2020	0	Recruitment Finished	
12	19/NE/0235	260081	An International, Phase 3, Multicenter, Randomized, Open Label Trial Comparing Balixafortide In combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer.	Number Agreed	40	40	Date Agreed	01/10/2020	0	01/10/2020	0	Recruitment Finished	

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
13	18/EM/0326	252819	A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma con	Number Agreed	32	32	Date Agreed	13/02/2020	40	13/02/2020	40	Recruitment Finished	
14	19/WM/0056	256301	Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease	Number Agreed	100	100	Date Agreed	06/02/2020	68	06/02/2020	68	Recruitment Finished	
15	19/SC/0416	269256	A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)	Number Agreed	24	24	Date Agreed	30/11/2020	12	30/11/2020	12	Recruitment Finished	
16	18/EE/0321	252391	Epidemiological analysis for Hereditary Angioedema Disease	Number Agreed	100	100	Date Agreed	28/02/2020	23	28/02/2020	23	Recruitment Finished	
17	19/LO/0855	260338	A Phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD L1 expression	Number Agreed	5	5	Date Agreed	25/05/2020	20	25/05/2020	20	Recruitment Finished	
18	18/NW/0765	250220	Testing a novel aid to diagnosis of peritonitis in clinic	Number Agreed	8	8	Date Agreed	29/09/2020	14	29/09/2020	14	Recruitment Finished	